Germline Testing for Prostate Cancer Prognosis: Implications for Active Surveillance

Area of Science:

• Oncology
• Genetics
• Genomic Medicine

Background:

• Prostate cancer (PCa) management benefits from understanding genetic predispositions.
• Identifying aggressive PCa early is crucial for effective treatment and improved outcomes.

Purpose of the Study:

• To review germline genetic testing's role in prostate cancer decision-making.
• To identify specific gene mutations associated with PCa aggressiveness, metastasis, and mortality.
• To explore the utility of polygenic risk scores in PCa prognosis.

Main Methods:

• Evidence-based review of available literature.
• Analysis of germline rare pathogenic mutations in key genes.
• Review of studies on genetic mutations and tumor grade reclassification in active surveillance.
• Examination of single nucleotide polymorphism-based polygenic risk scores.

Main Results:

• Germline genetic testing is supported for various prostate cancer decisions.
• Specific germline mutations are significantly linked to PCa aggressiveness, metastasis, and mortality.
• Genetic mutations show potential in predicting tumor grade reclassification for active surveillance.
• Polygenic risk scores can differentiate PCa aggressiveness and prognosis.

Conclusions:

• Routine germline genetic testing is recommended for prostate cancer patients.
• Understanding germline mutations aids in identifying and managing aggressive disease.
• Genetic profiling offers valuable insights for personalized prostate cancer care and active surveillance strategies.